Trial · NCT04712097
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) according to 2014 Lugano Response Criteria | From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8.5 years) | |
| Secondary | PFS as Determined by the Investigator | From randomization to the first occurrence of disease progression or death from any cause (up to approximately 8.5 years) | |
| Secondary | Complete Response Rate | Up to approximately 8.5 years | |
| Secondary | Objective Response Rate (ORR) | Up to approximately 8.5 years | |
| Secondary | Overall Survival (OS) | From randomization to death from any cause (up to approximately 8.5 years) | |
| Secondary | Duration of Objective Response (DOR) | From the first occurrence of a documented objective response (complete response or partial response) to disease progression or death from any cause, whichever occurs first (up to approximately 8.5 years) | |
| Secondary | Duration of Complete Reponse (DOCR) | From the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first (up to approximately 8.5 years) | |
| Secondary | Time to Deterioration in Physical Functioning and Fatigue, as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) | Up to approximately 8.5 years | |
| Secondary | Time to Deterioration in Lymphoma Symptoms, as Measured by the Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS) | Up to approximately 8.5 years | |
| Secondary | Percentage of Participants with Adverse Events (AEs) | Up to approximately 8.5 years | |
| Secondary | Serum Concentration of M + Len | Up to approximately 8.5 years | |
| Secondary | Area Under the Curve (AUC) of M + Len | Up to approximately 8.5 years | |
| Secondary | Percentage of Participants with Anti-Drug Antibodies (ADAs) | Up to approximately 8.5 years | |
| Secondary | Time to New Anti-Lymphoma Treatment (TTNALT) | From randomization to the first documented administration of a new anti-lymphoma treatment (up to approximately 8.5 years) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04712097/registered